Fukuoka University | Date: 2014-02-21
Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound.
Mayatec Co. and Fukuoka University | Date: 2012-01-18
Disclosed herein is a method for simply inducing an anti-apoptotic effect and/or an anti-necrotic effect in a living cell with good control without administering any drug. The method includes applying an alternating-current voltage to the living cell so that an electric current of 25 A or higher but 75 A or lower flows to induce an anti-apoptotic effect and/or an anti-necrotic effect in the living cell. The living cell used may be a cultured cell. The alternating-current voltage may be applied to a stage member on which a container holding the living cell is placed.
Fukuoka University | Date: 2011-12-12
A medicinal agent or a pharmaceutical composition, each of which comprises a biguanides agent or a pharmaceutically acceptable salt thereof as an active ingredient, and which can potentiate blood-brain barrier functions including tight junction capability and transcellular transport capability of a brain capillary endothelial cell and therefore can treat blood-brain barrier dysfunction syndrome.
Toyota Infotechnology Center Co., Fukuoka University and Toyota Jidosha Kabushiki Kaisha | Date: 2012-08-20
A wireless communication apparatus has a first communication unit configured to perform at least one of transmission and reception by using a multicarrier signal constituted by a plurality of subcarriers shaped by a band-limited pulse waveform; and second communication unit configured to perform at least one of transmission and reception by using a signal having a different modulation format or modulation constant from said signal of said first communication unit. Said first communication unit configured to perform communication without using at least one of said plurality of subcarriers, and said second communication unit configured to perform communication using a band of said subcarrier not used by said first communication unit.
Ishitsuka K.,Fukuoka University |
Tamura K.,Fukuoka University
The Lancet Oncology | Year: 2014
Adult T-cell leukaemia-lymphoma (ATL) is a malignancy of peripheral T lymphocytes caused by human T-lymphotropic virus type I (HTLV-1), and its prognosis is poor. There are an estimated 5 million to 20 million HTLV-1 infected individuals worldwide; their lifetime risk of developing ATL is 3-5%, and high HTLV-1 proviral loads have been shown to be an independent risk factor. Recent advances in the treatment of ATL are the introduction of treatment targeted against CC chemokine receptor 4 (CCR4), which is abundantly expressed on most ATL cells, and allogeneic haemopoietic stem-cell transplantation for aggressive ATL. Promising outcomes are also reported with early intervention for indolent ATL with interferon α and zidovudine. Clinical trials should incorporate a validated prognostic index to assess the results, because of the difficulties associated with undertaking large-scale trials and significant diversity of clinical features with ATL, even in the same clinical subtypes (acute, lymphoma, chronic, and smoldering). © 2014 Elsevier Ltd. Source